Pramipexole · Sifrol/Mirapex

Small molecule

WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn: Parkinson's Disease (FDA, approved 1997-07-01)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2023-01-09. The holder told FDA the product was no longer marketed and asked FDA to withdraw the approval (21 CFR 314.150(c)); FDA states that such a withdrawal is without prejudice to refiling. Approvals outside the US are listed below. The trials below are the product's evidence history.

Also approved (3)
JP
  • Parkinson's disease (approved as Sifrol, launched as BI-Sifrol by Nippon Boehringer Ingelheim)
Product first approved 2003pj.jiho.jp
EU
  • Signs and symptoms of idiopathic Parkinson's disease, alone or with levodopa (Mirapexin); also restless-legs syndrome
Product first approved 1998EMA
CA
  • MIRAPEX (pramipexole dihydrochloride monohydrate) is indicated for adults, as: • treatment of the signs and symptoms of idiopathic Parkinson’s disease. MIRAPEX may be used both as early therapy, without concomitant levodopa, and as an adjunct to levodopa. • symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome. The effectiveness of MIRAPEX used for longer than 12 weeks has not been systematically evaluated in controlled trials for Restless Legs Syndrome. The physician who elects to prescribe MIRAPEX for an extended time should periodically re-evaluate the long-term...
Product first approved 1998Health Canada

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (23)
Parkinson's Disease
NCT03329508 · Pharma Two B Ltd.
2018-01-19 – 2021-10-31 · Parkinson Disease, Early Parkinson's Disease
What this study did
NCT00577460 · Boehringer Ingelheim
2007-12 – 2010-06 · Parkinson Disease
What this study did
NCT00601523 · Boehringer Ingelheim
2008-01 – 2010-06 · Parkinson Disease
What this study did
NCT00275275 · Rajesh Pahwa, MD
2006-01 – 2008-05 · Parkinson Disease
What this study did
NCT00558025 · Boehringer Ingelheim
2007-10 – 2008-05 · Parkinson Disease
What this study did
NCT00240409 · Boehringer Ingelheim
2003-07 – 2004-08 · Parkinson Disease
What this study did
NCT00274131 · Boehringer Ingelheim
1998-12 – 2004-02 · Parkinson Disease
What this study did
NCT02172573 · Boehringer Ingelheim
1999-04 – 2000-07 · Parkinson Disease
What this study did
Other / comorbidity
NCT07664852 · Daniel Lindqvist
2026-10 – 2029-12-31 · Bipolar Disorder (BD)
What this study did
NCT05825235 · Region Skane
2023-04-21 – 2025-12-05 · Anhedonia, Depression
What this study did
NCT05355337 · Region Skane
2023-02-08 – 2025-06-04 · Psychiatric Disorders Mood, Anhedonia, Depression
What this study did
NCT03765138 · Research Foundation for Mental Hygiene, Inc.
2019-02-19 – 2019-08-26 · PTSD, MDD
What this study did
NCT01441284 · University of Pecs
2017-12 – 2018-12 · Essential Tremor
What this study did
NCT01320982 · Sheba Medical Center
2011-03 – 2012-07 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01106053 · Neuropsychiatric Research Institute, Fargo, North Dakota
2010-04 – 2011-07 · Binge Eating Disorder
What this study did
NCT00681863 · Boehringer Ingelheim
2008-05 – 2009-10 · Tourette Syndrome
What this study did
NCT00654498 · Boehringer Ingelheim
2008-04 – 2009-06 · Restless Legs Syndrome
What this study did
NCT00390689 · Boehringer Ingelheim
2006-10 – 2008-03 · Idiopathic Restless Legs Syndrome
What this study did
NCT00144209 · Boehringer Ingelheim
2003-02 – 2005-02 · Restless Legs Syndrome
What this study did
NCT00133198 · Boehringer Ingelheim
2004-04 – 2005-02 · Restless Legs Syndrome
What this study did
NCT00275457 · Boehringer Ingelheim
2002-10 – 2004-04 · Restless Legs Syndrome
What this study did
Phase 2/3 (2)
Parkinson's Disease
NCT00560508 · Boehringer Ingelheim
2007-11 – 2009-11 · Parkinson Disease
What this study did
Other / comorbidity
NCT04759703 · Massachusetts General Hospital
2022-01-24 – 2024-05-24 · Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
What this study did
Phase 2 (17)
Parkinson's Disease
NCT03845387 · Kissei Pharmaceutical Co., Ltd.
2019-02-26 – 2020-02-21 · Parkinson Disease
What this study did
NCT00096720 · Institute for Neurodegenerative Disorders
2004-02 – 2007-05 · Parkinson Disease, Parkinsonian Syndrome
What this study did
Other / comorbidity
NCT07022405 · Stanford University
2026-01-23 – 2030-08 · Depression - Major Depressive Disorder
What this study did
NCT06611592 · Clinical Academic Center (2CA-Braga)
2024-08-20 – 2028-08-20 · Obsessive-Compulsive Disorder
What this study did
NCT06269146 · University of California, San Diego
2024-05-13 – 2027-03 · Anxiety Disorders, Anxiety, Depression, Social Disconnection
What this study did
NCT06705478 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-05-17 – 2026-12-02 · Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
What this study did
NCT05401019 · Clinical Academic Center (2CA-Braga)
2022-06 – 2026-12 · Obsessive-Compulsive Disorder
What this study did
NCT04121091 · Region Skane
2019-10-04 – 2021-03-18 · Depression, Bipolar, Depression, Unipolar, Dysthymia, Anhedonia
What this study did
NCT01388478 · Virginia Commonwealth University
2011-07 – 2014-04 · Alzheimer's Disease
What this study did
NCT00893841 · Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.
2009-02 – 2013-01 · Bipolar Depression
What this study did
NCT00086307 · National Institute of Mental Health (NIMH)
2004-06 – 2010-03 · Major Depression
What this study did
NCT00558467 · Boehringer Ingelheim
2008-01 – 2009-06 · Tourette Syndrome
What this study did
NCT00689052 · Boehringer Ingelheim
2008-07 – 2008-11 · Fibromyalgia
What this study did
NCT00152997 · Boehringer Ingelheim
2004-08 – 2005-12 · Restless Legs Syndrome
What this study did
NCT00025792 · National Institute of Mental Health (NIMH)
2001-10 – 2005-11 · Bipolar Disorder
What this study did
NCT00239486 · Boehringer Ingelheim
2002-10 – 2004-04 · Restless Legs Syndrome
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT04160520 · East Carolina University
2019-10-28 – 2023-01-24 · Renal Colic
What this study did
NCT00600873 · Bennett, James P., Jr., M.D., Ph.D.
2007-08 – 2009-01 · Amyotrophic Lateral Sclerosis
What this study did
NCT00140218 · Bennett, James P., Jr., M.D., Ph.D.
2005-08 – 2006-12 · Amyotrophic Lateral Sclerosis
What this study did
Phase 1 (18)
Parkinson's Disease
NCT04249544 · Vanderbilt University Medical Center
2019-12-03 – 2022-09-01 · Parkinson Disease
What this study did
NCT00666653 · Oregon Health and Science University
2003-07 – 2007-05 · Parkinson's Disease
What this study did
Other / comorbidity
NCT07727785 · Boehringer Ingelheim
2026-08-05 – 2026-09-22 · Healthy
What this study did
NCT06457204 · Boehringer Ingelheim
2024-07-02 – 2024-08-12 · Healthy
What this study did
NCT03430596 · Shanghai Mental Health Center
2018-05-01 – 2021-12-30 · Extrapyramidal Syndrome
What this study did
NCT03842709 · University of New Mexico
2019-05-01 – 2021-02-15 · Chronic Pain
What this study did
NCT07519278 · Haisco Pharmaceutical Group Co., Ltd.
2017-03-16 – 2018-02-12 · Healthy
What this study did
NCT01651377 · Baylor College of Medicine
2011-10 – 2012-12 · Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
What this study did
NCT01214109 · Boehringer Ingelheim
2010-12 – 2011-01 · Healthy
What this study did
NCT00471588 · GlaxoSmithKline
2006-08 – 2007-12 · Obsessive-Compulsive Disorder
What this study did
NCT02262546 · Boehringer Ingelheim
2007-05 – 2007-10 · Healthy
What this study did
NCT02264132 · Boehringer Ingelheim
2006-09 – 2006-11 · Healthy
What this study did
NCT02261103 · Boehringer Ingelheim
2006-04 – 2006-07 · Healthy
What this study did
NCT02260024 · Boehringer Ingelheim
2005-10 – 2005-12 · Healthy
What this study did
NCT01074463 · Teva Pharmaceuticals USA
2005-02 – 2005-03 · Healthy
What this study did
NCT01074450 · Teva Pharmaceuticals USA
2005-02 – 2005-03 · Healthy
What this study did
NCT02261090 · Boehringer Ingelheim
2004-06 – 2004-09 · Healthy
What this study did
Phase 4 (25)
Parkinson's Disease
NCT01673724 · Sandoz
2012-02 – 2016-05-23 · Parkinson's Disease
What this study did
NCT00144300 · Boehringer Ingelheim
2005-01 – 2010-09 · Parkinson Disease
What this study did
NCT00321854 · Boehringer Ingelheim
2006-05 – 2009-04 · Parkinson Disease
What this study did
NCT00297778 · Boehringer Ingelheim
2006-03 – 2008-05 · Parkinson Disease, Depression
What this study did
NCT00399477 · Teva Neuroscience, Inc.
2006-10 – 2007-07 · Parkinson's Disease
What this study did
NCT02231905 · Boehringer Ingelheim
2004-01 – 2004-11 · Parkinson Disease
What this study did
NCT02233023 · Boehringer Ingelheim
1998-06 – 2000-06 · Parkinson Disease
What this study did
Other / comorbidity
NCT06580041 · University of California, San Francisco
2024-11-12 – 2029-09-01 · Major Depressive Disorder, Depression, Depressive Disorder, Major
What this study did
NCT05003648 · Massachusetts General Hospital
2023-04-01 – 2026-09-01 · Adrenoleukodystrophy, Restless Legs Syndrome
What this study did
NCT04936126 · All India Institute of Medical Sciences, Bhubaneswar
2021-08-07 – 2024-09-07 · Treatment Resistant Depression
What this study did
NCT03817554 · Dong Jie
2019-07-01 – 2020-08-31 · Restless Legs Syndrome
What this study did
NCT02397837 · Brigham and Women's Hospital
2014-10 – 2018-07-26 · Bipolar Disorder
What this study did
NCT02033369 · New York State Psychiatric Institute
2014-02 – 2017-07 · Major Depressive Disorder
What this study did
NCT02025608 · Mauro Manconi
2013-12 – 2016-12-31 · Restless Legs Syndrome
What this study did
NCT01066897 · Stanford University
2010-02 – 2013-02 · Depression
What this study did
NCT00597896 · Northwell Health
2005-10 – 2011-04 · Bipolar Disorder
What this study did
NCT00344994 · Augusta University
2006-05 – 2010-04 · Restless Legs Syndrome
What this study did
NCT00472199 · Boehringer Ingelheim
2007-05 – 2008-07 · Restless Legs Syndrome
What this study did
NCT00231959 · Massachusetts General Hospital
2003-09 – 2008-04 · Depression
What this study did
NCT00375284 · Boehringer Ingelheim
2006-09 – 2007-07 · Restless Legs Syndrome
What this study did
NCT00356096 · Boehringer Ingelheim
2006-07 – 2007-06 · Restless Legs Syndrome, Depression
What this study did
NCT00349531 · Boehringer Ingelheim
2006-07 – 2007-05 · Restless Legs Syndrome
What this study did
NCT00102856 · University Hospital Muenster
2005-01 – 2006-06 · Healthy
What this study did
Early phase / not applicable (4)
Parkinson's Disease
NCT04275492 · First Affiliated Hospital of Zhejiang University
2020-07-24 – 2020-12-01 · Parkinson's Disease
What this study did
NCT01470859 · Huashan Hospital
2011-12 – 2014-08 · Idiopathic Parkinson's Disease
What this study did
Other / comorbidity
NCT03681509 · University of Oxford
2018-09-01 – 2019-11-01 · Emotions, Motivation, Reward, Dopamine
What this study did
NCT02660060 · Dexa Medica Group
2015-05 – 2015-06 · Healthy
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Parkinson's Disease
NCT01191944 · Boehringer Ingelheim
2010-08 – 2012-01 · Parkinson Disease
What this study did
NCT01007864 · Desitin Arzneimittel GmbH
2010-01 – 2011-12 · Idiopathic Parkinson's Disease
What this study did
NCT00335166 · Solvay Pharmaceuticals
2006-11 – 2008-02 · Early Stage Parkinson Disease
What this study did
Other / comorbidity
NCT00991276 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009-12 – 2011-06 · Restless Legs Syndrome
What this study did
Phase 2 (2)
Parkinson's Disease
NCT02347059 · University of Toronto
2015-01 – 2016-08 · Parkinson's Disease
What this study did
Phase 1 (2)
Other / comorbidity
NCT07844954 · The Third Xiangya Hospital of Central South University
2026-09-30 – 2027-12-31 · Healthy Participants
What this study did
NCT07240675 · Hunan Kelun Pharmaceutical Co., Ltd.
2025-11-26 – 2026-09-30 · Healthy Volunteers
What this study did
Phase 4 (1)
Parkinson's Disease
NCT01048229 · Qualissima
2008-10 – 2010-03 · Early-stage Parkinson's Disease
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 2/3 (1)
Parkinson's Disease
NCT01968460 · Pharma Two B Ltd.
2013-12 – 2015-06 · Parkinson's Disease
What this study did

Competitive landscape

This drug's own stage for Parkinson's Disease: US approval withdrawn. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pramipexole (Sifrol/Mirapex): this drugUS approval withdrawnSmall moleculeDopamine D2/D3 receptorsPartial signal
NCT02177357: UPDRS Part II, Part III and Parts II+III combined: pramipexole significantly more effective than placebo at 15 weeks
Amantadine ER (Gocovri / ADS-5102)ApprovedSmall moleculeNMDA receptorReliable signal
NCT02274766: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): ADS-5102 (Amantadine HCl Extended Release) -20.7 units on a scale (Standard Error 2.2) vs Placebo -6.3 units on a scale (Standard Error 2.08)
NCT02136914: Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12 (Baseline to Week 12): ADS-5102 (340 mg) -15.9 units on a scale (Standard Error 1.62) vs Placebo -8 units on a scale (Standard Error 1.64)
Apomorphine (Apokyn)ApprovedSmall moleculeDopamine receptor (non-ergoline agonist)Weak signalNo reviewed efficacy summary in this indication
Apomorphine (Onapgo)ApprovedSmall moleculeDopamine receptor (non-ergoline agonist)Reliable signal
NCT02006121: Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Apomorphine Hydrochloride -2.61 Hours (95% CI -3.43 to -1.8) vs Placebo -0.75 Hours (95% CI -1.66 to 0.16)
Crexont (IPX203)ApprovedSmall moleculedopamine precursorReliable signal
NCT03670953: Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081)
Entacapone (Comtess)ApprovedSmall moleculeCOMTnot yet gradedNo reviewed efficacy summary in this indication
Foslevodopa / Foscarbidopa (Vyalev)ApprovedSmall moleculedopamine precursorReliable signal
NCT04380142: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5)
Istradefylline (Nourianz)ApprovedSmall moleculeadenosine A2APartial signal
NCT00199407: Placebo-corrected reduction in daily OFF time at endpoint: 4.6% (equivalent to 0.7 hours), P=0.03, favoring istradefylline 20mg/day over placebo.
NCT01968031: Change from baseline in daily OFF time at week 12, istradefylline 20 mg and 40 mg vs placebo: no statistically significant difference for either dose (Kyowa Hakko Kirin topline release, 13 Dec 2016; no effect estimate published in the release). missed
Levodopa (Inbrija)ApprovedSmall moleculedopamine precursorPartial signal
NCT02240030: UPDRS motor score change, predose to 30 min post-dose at week 12: CVT-301 84 mg -9.83 vs placebo -5.91; difference -3.92 (95% CI -6.84 to -1.00), p=0.0088 (LeWitt et al., Lancet Neurol 2019)
Levodopa-Carbidopa Intestinal Gel (Duopa)ApprovedSmall moleculedopamine precursorWeak signal
NCT00357994: Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66)
Opicapone (Ongentys)ApprovedSmall moleculeCOMTPartial signal
NCT04978597: Change in MDS-UPDRS Part III total score from baseline to Week 24: -6.5 opicapone vs -4.3 placebo; difference -2.2 (95% CI -3.9, -0.5) favoring opicapone, p=0.010
NCT01568073: Change in absolute OFF-time vs placebo: opicapone 50 mg -60.8 min (95% CI -97.2 to -24.4), p=0.0015, and non-inferior to entacapone (-26.2 min, p=0.0051); opicapone 5 mg p=0.056 and 25 mg p=0.080 vs placebo (BIPARK-1, Lancet Neurol 2016).
Parcopa
ApprovedUS marketing discontinued
Small moleculedopamine precursorPartial signal
NCT00139880: Onset times were similar: 43 minutes vs 47 minutes (Sinemet vs Parcopa, respectively)
NCT00139867: Patient preference: 45% preferred Parcopa (carbidopa-levodopa orally disintegrating tablets), 35% had no preference, 20% preferred conventional carbidopa-levodopa tablets.
Pramipexole ER (Mirapex ER)ApprovedSmall moleculeDopamine D2 / D3 receptorsReliable signal
NCT00466167: UPDRS II+III score change at week 18 (adjusted mean, points): extended release -11.0, immediate release -12.8, placebo -6.1; ER vs placebo p=0.0001, IR vs placebo p<0.0001. The registry labels the unit 'percentage of change from baseline'; the publication reports score changes from baseline means of 40.0 to 41.7.
NCT00479401: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Total Score (baseline and after 33 weeks treatment): Pramipexole Extended Release (PPX ER) -8.6 units on a scale (95% CI -9.9 to -7.2) vs Pramipexole Immediate Release (PPX IR) -8.8 units on a scale (95% CI -10.2 to -7.4) vs Placebo -3.8 units on a scale (95% CI -5.9 to -1.8)
Rasagiline (Azilect)ApprovedSmall moleculeMAO-BReliable signal
NCT01479530: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 4, 8, 12, and 16): Azilect® -1.25 hours (Standard Error 0.16) vs Placebo -0.76 hours (Standard Error 0.16)
NCT01268891: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary (Baseline and Weeks 6, 10, 14, and 18): Azilect® -1.59 hours (Standard Error 0.25) vs Placebo -1.24 hours (Standard Error 0.26) missed
Rotigotine (Neupro)ApprovedSmall moleculeDopamine receptorsWeak signal
NCT01628926: UPDRS Part III change at 16 weeks, rotigotine vs placebo: -6.4 ± 1.2 (95% CI -8.7 to -4.1; p<0.001); non-inferior to ropinirole (n=420).
NCT00244387: Absolute change in off-time vs baseline: rotigotine -2.5h, pramipexole -2.8h, placebo -0.9h; vs placebo: rotigotine -1.58h (95% CI -2.27 to -0.90, p<0.0001), pramipexole -1.94h (95% CI -2.63 to -1.25, p<0.0001); responder rate (>=30% off-time reduction): rotigotine 59.7%, pramipexole 67%, placebo 35%
Rytary (IPX066)ApprovedSmall moleculedopamine precursorReliable signal
NCT00974974: Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81)
NCT00880620: Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30 (Week 30): IPX066 145mg LD -11.7 units on a scale (Standard Deviation 10.97) | IPX066 245 mg LD -12.9 units on a scale (Standard Deviation 11.42) | IPX066 390 mg LD -14.9 units on a scale (Standard Deviation 11.85) vs Placebo -0.6 units on a scale (Standard Deviation 10.37)
Safinamide (Xadago)ApprovedSmall moleculeMAO-BPartial signal
NCT03881371: Change From Baseline to Week 16 in the Mean Total Daily "OFF" Time (At baseline and Week 16): Safinamide -1.93 Hours (Standard Deviation 2.556) vs Placebo -0.88 Hours (Standard Deviation 2.543)
NCT00605683: Primary endpoint (UPDRS III change, baseline to week 24), full ITT population (n=679): safinamide 100mg/d vs placebo borderline, P=0.073 (not met). In the pre-specified DA-monotherapy subgroup (n=666): safinamide 100mg/d significantly improved UPDRS III vs placebo, P=0.0396.
Tavapadon (Juvmo)ApprovedSmall moleculeD1/D5Reliable signal
NCT04223193: Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score (Week 26): Tavapadon -10.3 score on a scale (Standard Error 0.99) vs Placebo -1.2 score on a scale (Standard Error 0.89)
NCT04201093: Change From Baseline in the MDS-UPDRS Parts II and III Combined Score (Week 26): Tavapadon 5 mg -9.7 score on a scale (Standard Error 0.86) | Tavapadon 15 mg -10.2 score on a scale (Standard Error 0.88) vs Placebo 1.8 score on a scale (Standard Error 0.82)
AmbroxolPhase 3Small moleculeGBA1/glucocerebrosidasePartial signal
NCT05287503: Primary (MoCA change at 52 weeks): -0·69 ambroxol vs 0·19 placebo (n=28 per group); mean difference -1·18 (95%CI -2·63 to 0·27, p=0·053); adjusted mean difference -1·05 (95%CI -2·17 to -0·06, p=0·030), significantly worse with ambroxol. missed
Bemdaneprocel (MSK-DA01)Phase 3Cell therapyMidbrain dopaminergic neuronsWeak signalFeatured results are safety only in this race
BIIB122 / DNL151 (LRRK2 Inhibitor)Phase 3Small moleculeLRRK2Weak signal
NCT05348785: Phase 2b LUMA (n=648, randomized, placebo-controlled) did not slow confirmed clinical worsening; Biogen and Denali said in May 2026 that they would discontinue BIIB122/DNL151 development in idiopathic Parkinson's disease. Denali continues the Phase 2a BEACON study in LRRK2-variant carriers. missed
BuntanetapPhase 3Small moleculeAPP/tau/alpha-synuclein/TDP-43 (translation)Partial signal
NCT05357989: Primary MDS-UPDRS Part II change at month 6: 0.57 (10 mg) vs -0.10 (placebo); -0.04 (20 mg) vs -0.10 (placebo). missed
Droxidopa (Northera)Phase 3Small moleculenorepinephrine precursorPartial signalNo reviewed efficacy summary in this indication
HRG2010Phase 3Small moleculeCentral dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide)Partial signal
NCT06596876: Primary endpoint, change from baseline in mean daily 'off' time at the end of double-blind treatment: HRG2010 shortened 'off' time compared with sustained-release carbidopa/levodopa, per Hengrui; the key secondary (good 'on' time without troublesome dyskinesia) was also improved. The company disclosed no numbers.
IncobotulinumtoxinA (Xeomin)Phase 3Protein / enzyme therapeuticacetylcholine releasenot yet graded
NCT02091739: MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 (Baseline and Week 4): MP: IncobotulinumtoxinA (Xeomin) (75 Units) -0.06 gram per minute (g/min) (Standard Error 0.027) | MP: IncobotulinumtoxinA (Xeomin) (100 Units) -0.13 gram per minute (g/min) (Standard Error 0.026) vs MP: Placebo -0.04 gram per minute (g/min) (Standard Error 0.033) phase 3 result · pivotal pending
Levodopa / Carbidopa (ND0612) (Onerji)Phase 3Small moleculedopamine precursorPartial signal
NCT02577523: Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5)
Piribedil (Clarium)Phase 3Small moleculeD2/D3Partial signal
NCT01007864: Primary endpoint (median reaction time, TAP battery vigilance subtest, minutes 16-30, end of treatment): piribedil 996 ms vs comparator (pramipexole/ropinirole) 954 ms; P=0.68 - no significant difference. missed
Pramipexole / Rasagiline (P2B001)Phase 3Small moleculedopamine / MAO-BReliable signal
NCT03329508: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160). (baseline to week 12): P2B001 -7.98 score on a scale (Standard Error 0.6) vs Rasagiline Capsule -4.69 score on a scale (Standard Error 0.61) vs Pramipexole Capsule -5.32 score on a scale (Standard Error 0.61) vs Pramipexole Extended Release -8.35 score on a scale (Standard Error 0.86)
NCT01968460: Total UPDRS I, II, III Scores (Week 12): P2B001 Treatment A -5.97 units on a scale (Standard Error 0.94) | P2B001 Treatment B -5.15 units on a scale (Standard Error 0.9) vs Placebo -1.31 units on a scale (Standard Error 0.88)
PrasinezumabPhase 3Monoclonal antibodyalpha-synucleinnot yet gradedNo reviewed efficacy summary in this indication
Rotigotine (LY03003) (Jinyouping)Phase 3Small moleculeDopamine receptorsPartial signal
NCT04571164: Change from baseline in UPDRS Part II+III total score: LY03003 -11.8 vs placebo -5.6 (P<0.001)
Solengepras (CVN424)Phase 3Small moleculeGPR6Weak signalFeatured results are safety only in this race
Trigel (Lecigon)Phase 3Small moleculeCOMTPartial signalFeatured results are non-efficacy only in this race
BHV-8000Phase 2/3Small moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
VG081821ACPhase 2/3Small moleculeadenosine A2Anot yet gradedNo reviewed efficacy summary in this indication
AAV-GAD Gene TherapyPhase 2Gene therapy / editingGlutamic acid decarboxylase (GAD) gene delivered to the subthalamic nucleusWeak signal
NCT05603312: Treatment-related adverse events: 0/5 AAV-GAD low dose, 1/5 AAV-GAD high dose, and 0/4 sham surgery; treatment-related serious adverse events: 0/5, 0/5, and 0/4, respectively.
AFFITOPE PD01A / ACI-7104.056Phase 2Vaccinealpha-synucleinnot yet gradedNo reviewed efficacy summary in this indication
Ametefgene ParvecPhase 2Gene therapy / editingGDNFWeak signalFeatured results are safety only in this race
AP-472Phase 2Small moleculemGlu4not yet gradedNo reviewed efficacy summary in this indication
BezisterimPhase 2Small moleculeERK/NF-kB inflammatoryPartial signal
NCT05083260: Registered primary objectives were safety/drug-interaction; exploratory motor finding: NE3107 (bezisterim) + levodopa improved MDS-UPDRS Part 3 motor score >=3 points more than levodopa alone; roughly 6 points more in patients under age 70
Cannabidiol (Kanbis)Phase 2Small moleculecannabinoidnot yet gradedNo reviewed efficacy summary in this indication
Carbidopa / Levodopa (WD-1603)Phase 2Small moleculedopamine precursorPartial signal
NCT05036473: Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003)
CNM-Au8Phase 2Nanoparticlemitochondrial energy metabolismWeak signal
NCT03815916: NAD+/NADH ratio (primary endpoint) in the REPAIR-PD cohort (NCT03815916): +6.8% increase with CNM-Au8 (0.386 units), p=0.108 (paired t-test) — not statistically significant on its own; significance (p=0.037) was reached only in the prespecified integrated analysis combining the PD and MS (REPAIR-MS) cohorts together. missed
CPL500036Phase 2Small moleculePDE10APartial signal
NCT05297201: Change from baseline in total UDysRS score at Week 4 (LS mean difference vs placebo): 20 mg dose -12.30 units (p<0.001, Cohen's d 0.90); 40 mg dose -13.58 units (p<0.001, Cohen's d 1.00)
ENERGI-F705Phase 2Small moleculealpha-synuclein / mitochondrial ATPnot yet gradedNo reviewed efficacy summary in this indication
ENT-01Phase 2Small moleculeenteric neuronPartial signal
NCT03781791: Weekly complete spontaneous bowel movements (CSBM): rose from 0.7 to 3.2 with ENT-01 vs 0.7 to 1.2 with placebo (P < 0.001), n=150 (Camilleri et al., Ann Intern Med 2022).
Exenatide (PT320)Phase 2PeptideGLP-1 receptorPartial signal
NCT04269642: Primary endpoint, mean change in MDS-UPDRS part 3 score: no statistical significance between test group 1 and the placebo group (p=0.7355); in test group 2 motor symptoms improved but again without statistical significance versus placebo (p=0.5042). missed
ExidavnemabPhase 2Monoclonal antibodyalpha-synucleinWeak signalNo reviewed efficacy summary in this indication
GlovadalenPhase 2Small moleculeD1 receptorPartial signal
NCT06055985: Change from baseline to Day 70 in average hours/day of OFF time (ATLANTIS trial, n=207, 1:1:1 low-dose/high-dose/placebo): low-dose UCB0022 (glovadalen) reduced OFF time by 0.8 hours/day vs placebo; high-dose reduced it by 0.45 hours/day vs placebo
GT-02287Phase 2Small moleculeGBA1/glucocerebrosidasenot yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
KM-819Phase 2Small moleculeFAF1Weak signalFeatured results are safety only in this race
Lenrispodun (ITI-214)Phase 2Small moleculePDE1Partial signalNo reviewed efficacy summary in this indication
Lu AF28996Phase 2Small moleculeD1/D2Weak signalNo reviewed efficacy summary in this indication
Matsupexole (KDT-3594)Phase 2Small moleculeD2/D3Partial signalNo reviewed efficacy summary in this indication
Mesdopetam (IRL790)Phase 2Small moleculeD3Partial signal
NCT04435431: Primary endpoint, change in daily hours of good ON-time (ON-time without troublesome dyskinesia), mesdopetam vs placebo at 12 weeks: not statistically significant. Secondary endpoint UDysRS (ON-phase dyskinesia) improved at 7.5 mg bid (nominal p = 0.026). missed
NCT03368170: Unified Dyskinesia Rating Scale (UDysRS) (Baseline and 4 weeks): Mesdopetam -4.2 score on a scale (95% CI -7.3 to -1) vs Placebo -7 score on a scale (95% CI -10.3 to -3.8) missed
MT101-5Phase 2Small molecule—Partial signalNo reviewed efficacy summary in this indication
NEU-411Phase 2Small moleculeLRRK2not yet gradedNo reviewed efficacy summary in this indication
NouvNeu001Phase 2Cell therapydopaminergic neuron replacementnot yet gradedNo reviewed efficacy summary in this indication
ParunoflastPhase 2Small moleculeNLRP3 inflammasome, NLRP3Weak signalFeatured results are safety only in this race
Pirepemat (IRL752)Phase 2Small molecule5-HT/norepinephrinePartial signal
NCT05258071: Change in Falls Frequency as Assessed With Fall Diary From Baseline Period (4 Weeks Prior to Randomization) to the End of Treatment. (Baseline to end of full dose treatment (up to Day 84).): Pirepemat 300 mg 76.9 % of baseline fall rate (Standard Deviation 72.05) | Pirepemat 600 mg 64.5 % of baseline fall rate (Standard Deviation 49.18) vs Placebo 68.9 % of baseline fall rate (Standard Deviation 90.22) missed
Pramipexole ER / Aprepitant (CTC-413)Phase 2CombinationDopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component)Weak signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 65 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sifrol/Mirapex (Pramipexole) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Anxiety Disorders, Anxiety, Depression, Social DisconnectionActive not recruiting
Est. primary completion 2026-11 · NCT06269146 · CT.gov ↗
What to watch
2028 (1)
August 2028 (1)
Phase 2Obsessive-Compulsive DisorderRecruiting
Est. primary completion 2028-08-20 · NCT06611592 · CT.gov ↗
What to watch
2029 (2)
September 2029 (1)
Phase 4Major Depressive Disorder, Depression, Depressive Disorder, MajorEnrolling by invitation
Est. primary completion 2029-09-01 · NCT06580041 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Bipolar Disorder (BD)Recruiting
Est. primary completion 2029-12-31 · NCT07664852 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Phase 2Depression - Major Depressive DisorderRecruiting
Est. primary completion 2030-08 · NCT07022405 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 January 2023WithdrawalFDA withdraws approval of NDA 020667 (Federal Register 2022-26661)
US, FDA · Source ↗